Enterprise Therapeutics focuses on discovery and development of therapies to improve outcomes for patients with chronic respiratory diseases by targeting underlying mechanisms of mucus congestion. Its lead programme, ETD001, is a novel low‑molecular‑weight, first‑in‑class candidate that targets the ENaC ion channel to increase airway hydration and mucus clearance and is designed for long‑acting, durable target engagement. The company plans a Phase 2a cross‑over clinical trial assessing FEV1 in people with cystic fibrosis who are ineligible for or not receiving CFTR modulators. Enterprise’s pipeline includes additional preclinical programmes addressing mucus congestion in cystic fibrosis, COPD and severe asthma. The company has established an Italian subsidiary to support R&D and will expand clinical investigator sites in Italy as part of its clinical activities. Funding from the raise is intended to enable progression of ETD001 to clinical proof of concept and advance other preclinical programmes. Enterprise Therapeutics develops muco-regulatory therapies aimed at treating respiratory diseases where mucus obstruction impairs lung function. Its drug discovery pipeline targets ion channels TMEM16A and ENaC to increase mucus hydration and clearance. The company has also identified novel targets and compounds that reduce mucus production, a complementary approach to hydration-focused therapies. Enterprise intends to advance its pipeline into clinical development using the newly raised funds. Its programs target high‑unmet‑need indications including cystic fibrosis, chronic obstructive pulmonary disease and severe asthma. Epidarex Capital has been involved with the company since an initial investment in 2014 and remains a backer. Enterprise Therapeutics is a drug discovery company focused on research and development of novel therapies for respiratory diseases. The company leverages its bronchosphere technology platform, a miniaturised model of the human airway. Bronchospheres are used to enable high-throughput drug and target discovery and to facilitate development of new classes of therapeutics for cystic fibrosis. Enterprise Therapeutics has won funding from the Cystic Fibrosis Trust to identify new drug mechanisms for CF and to support pioneering research. Company leadership commented that the Trust’s funding will enable critical research and drive greater scientific understanding of CF, and the Trust expressed optimism that the technology could bring hope to people living with CF. The company is based in Brighton, England. Enterprise Therapeutics focuses on discovering novel muco-regulatory therapies that either increase mucus clearance or reduce mucus production to alleviate symptoms and complications of respiratory diseases. Its programs target treatments for cystic fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and severe asthma. The company is advancing three discovery projects toward drug candidate selection. Management says the work aims to move into patient efficacy evaluation once candidates are selected. The announcement emphasizes recent milestone achievement across all three projects. The company is headquartered in Brighton, England. Enterprise Therapeutics is a Brighton, UK-based drug discovery company focused on developing novel disease-modifying therapeutics for respiratory diseases. It targets key drivers of pathology and progression in cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma. The company was formed in May 2014 and is led by CSO Martin Gosling. Enterprise operates from the Sussex Innovation Centre at the University of Sussex. In early 2015 it initiated drug discovery and target-identification programs which it intends to consolidate and accelerate with new funding.

Total raised

$79M

Funding rounds

5

Latest round

Series B

Latest activity

Jan 2024